Iboga: The Plant Behind the Medicine

Most of what gets written about ibogaine today treats it as a molecule. Eighteen carbons, two nitrogens, a Schedule I designation, a clinical protocol, a Stanford study. All true. All recent. All American. Long before any of that, ibogaine was something else: a chemical inside the bark of a slow-growing shrub in central Africa, in a plant whose name in the local language predates the modern word by centuries. The shrub is called iboga, Tabernanthe iboga, and if you are about to consider a treatment that uses one of its compounds, it is worth knowing what the plant actually is.

Part 1. The Plant

Tabernanthe iboga is a small to medium evergreen shrub, four to six feet tall in most growing conditions, occasionally reaching higher under a forest canopy. It has long, narrow, oval leaves in opposing pairs, small whitish or pinkish star-shaped flowers, and small orange fruit, technically drupes, that grow in clusters. None of the visible parts of the plant are dramatic. Walking through a Gabonese rainforest, you would not necessarily notice iboga unless someone pointed it out.

It belongs to the Apocynaceae family, the same plant family as periwinkle and oleander. Many Apocynaceae produce alkaloids; iboga is one of the more pharmacologically interesting members of the family.

It grows wild across a band of west-central African rainforest: primarily Gabon, where the cultural relationship with the plant is deepest, but also Cameroon, the Republic of the Congo, parts of Equatorial Guinea, and the western Democratic Republic of the Congo. It is not found wild anywhere else on Earth. Attempts to cultivate it outside Africa exist, on private property in places like Hawaii and Costa Rica, but the commercial supply is still overwhelmingly African.

The plant matures slowly. Estimates vary, but the consensus is that a wild iboga plant needs roughly seven to ten years before the root system is large enough to be a useful medicinal harvest. That timeline matters more than it sounds like it should. A plant that takes a decade to replace cannot be wild-harvested at industrial scale without consequence. We will come back to this.

Part 2. What's Inside It

The medicinally interesting part of the iboga plant is the root bark, specifically the inner bark of the taproot. The leaves and fruit are not biologically inert, but the alkaloid concentration in the root bark is meaningfully higher than anywhere else in the plant.

The root bark contains more than a dozen indole alkaloids. The most studied is ibogaine, but ibogaine is not alone. The other major alkaloids include:

• Ibogamine
• Tabernanthine
• Coronaridine
• Iboxygaine
• Ibogaline

The total alkaloid content of root bark varies by plant age, location, and season, but typical concentrations land around 5% to 6% by weight. Ibogaine itself is the majority of that fraction, roughly 80%, with the remainder split among ibogaline, ibogamine, tabernanthine, and the others.

This is one of the most important and least understood distinctions in modern ibogaine treatment. A Bwiti initiate consuming raw root bark is taking ibogaine and eleven other alkaloids in a fixed natural ratio. A Mexican clinic patient swallowing a gel cap of ibogaine HCl is taking purified ibogaine, alone. Whether the difference matters clinically is an open question. Some practitioners argue the full-spectrum extract produces a meaningfully different experience. Others argue ibogaine HCl is cleaner, safer, and more dose-precise. Both camps cite real evidence; neither has settled the question.

If you want to read the deeper version of this, our companion article Iboga vs. Ibogaine: What's the Difference? walks through it in more detail.

Part 3. Who Found It First

The first people to figure out what iboga does were not chemists. They were the Babongo, the central African forest people sometimes called Pygmies, who almost every Bwiti origin myth credits as the original keepers of iboga's power. One version, recorded by anthropologist James Fernandez in his foundational 1982 ethnography Bwiti, tells the story this way: the creator god Zame ye Mebege saw a Babongo man named Bitamu high in an Atanga tree gathering fruit. He made him fall. Bitamu died. Zame took his spirit, cut off the little fingers and little toes of the cadaver, and planted them in the forest. They grew into iboga.

Whether or not you believe that as theology, it is significant as anthropology: the founding story of Bwiti, the religion that built itself around iboga, begins by acknowledging that the religion inherited the medicine from someone else.

The Bwiti are not a tribe. Bwiti is a religion, or more accurately a family of related traditions, practiced primarily in Gabon (with adherents in Cameroon and the Republic of the Congo). They formalized iboga's use into multi-day initiation rites, structured with continuous polyrhythmic music, fire, the presence of a senior initiator, and doses of root bark far higher than anything a Western clinic would deliver. The full story, including what the published ethnographic research suggests the ceremonial music may do pharmacologically, is in our companion article on iboga and the Bwiti tradition.

What matters here is the timeline. By the time the first French chemists isolated ibogaine in 1901, the Bwiti had been using iboga ceremonially for an unknown but multi-century stretch. Iboga is one of the very few cases in the history of medicine where the traditional dose range, the safety knowledge, the framing of the experience, and even some of the contraindications were all worked out empirically by an indigenous culture long before any laboratory got involved. Western medicine, in this case, is the latecomer.

Part 4. From Rainforest to Gel Cap

The path from a Gabonese shrub to a Mexican clinic's pharmacy goes through several steps, and most of them are less than fully transparent.

Wild harvest in Gabon. Bwiti communities historically harvested iboga for their own ceremonial use, with cultural rules around when and how much. Commercial demand from Western buyers has, predictably, broken those rules. Wild iboga is now considered conservation-vulnerable; estimates of the remaining wild population vary widely and most are not reassuring.

Semi-synthesis from Voacanga africana. Increasingly, the ibogaine used in Western clinics is not extracted from iboga at all. It is semi-synthesized from Voacanga africana, a related Apocynaceae shrub native to much of West Africa, whose root bark contains voacangine, a precursor alkaloid that can be chemically converted to ibogaine at roughly six times the yield of direct extraction from T. iboga. Voacanga grows faster, can be harvested without killing the tree, and is far less culturally loaded, which is why much of the legitimate pharmaceutical supply chain, including the long-standing Spanish manufacturer Covex, has moved this way.

Gabonese sovereignty. In June 2000, the Gabonese Council of Ministers declared iboga a national strategic reserve. Export was tightened in 2019. On April 30, 2026, the Council of Ministers adopted a new decree consecrating iboga and its derivatives, including ibogaine itself, as patrimoine stratégique national (strategic national heritage). Any research, exploitation, transformation, or export now requires prior authorization from the Ministry of Culture, following review by an inter-ministerial technical commission. The decree also creates a sovereign Iboga Fund (Fonds Souverain Iboga) and establishes a benefit-sharing mechanism with local communities holding traditional knowledge of the plant.

What this means in practice: any Western treatment industry serious about its supply chain is going to have to answer for where its ibogaine actually came from. "Synthesized from Voacanga" is, for now, the cleanest answer. "Wild-harvested in Gabon without authorization" is increasingly the legally and ethically vulnerable one.

What This Means for People Considering Treatment

You do not need to know any of this to receive ibogaine treatment safely. The clinic will not test you on it. You will not be quizzed about Tabernanthe iboga or about Bwiti or about voacangine before they put an IV in your arm.

But: this medicine has a backstory longer than the molecule, and the people who figured out most of what we know about how to use it did not get cited in the press releases. Knowing the plant is one of the small ways an American patient can take this experience more seriously than the marketing wants you to.

If you want to keep reading: the Bwiti tradition piece goes deeper on the culture, the iboga-vs-ibogaine piece goes deeper on the chemistry, and the clinic directory is where you go when you want to know who is delivering this responsibly today.